This review highlights recent evidence from clinical and basic science studies supporting a role for estrogen in neuroprotection. Accumulated clinical evidence suggests that estrogen exposure decreases the risk and delays the onset and progression of Alzheimer's disease and schizophrenia, and may also enhance recovery from traumatic neurological injury such as stroke. Recent basic science studies show that not only does exogenous estradiol decrease the response to various forms of insult, but the brain itself upregulates both estrogen synthesis and estrogen receptor expression at sites of injury. Thus, our view of the role of estrogen in neural function must be broadened to include not only its function in neuroendocrine regulation and reproductive behaviors, but also to include a direct protective role in response to degenerative disease or injury. Estrogen may play this protective role through several routes. Key among these are estrogen dependent alterations in cell survival, axonal sprouting, regenerative responses, enhanced synaptic transmission and enhanced neurogenesis. Some of the mechanisms underlying these eects are independent of the classically de®ned nuclear estrogen receptors and involve unidenti®ed membrane receptors, direct modulation of neurotransmitter receptor function, or the known anti-oxidant activities of estrogen. Other neuroprotective eects of estrogen do depend on the classical nuclear estrogen receptor, through which estrogen alters expression of estrogen responsive genes that play a role in apoptosis, axonal regeneration, or general trophic support. Yet another possibility is that estrogen receptors in the membrane or cytoplasm alter phosphorylation cascades through direct interactions with protein kinases or that estrogen receptor signaling may converge with signaling by other trophic molecules to confer resistance to injury. Although there is clear evidence that estradiol exposure can be deleterious to some neuronal populations, the potential clinical bene®ts of estrogen treatment for enhancing cognitive function may outweigh the associated central and peripheral risks. Exciting and important avenues for future investigation into the protective eects of estrogen include the optimal ligand and doses that can be used clinically to confer bene®t without undue risk, modulation of neurotrophin and neurotrophin receptor expression, interaction of estrogen with regulated cofactors and coactivators that couple estrogen receptors to basal transcriptional machinery, interactions of estrogen with other survival and regeneration promoting factors, potential estrogenic eects on neuronal replenishment, and modulation of phenotypic choices by neural stem cells. 7
Introduction
The rush over the last decade to elucidate the neuroprotective eects of estrogen in disease or injury of the nervous system was precipitated by a series of ®ndings which forced recognition of the potential impact of gonadal steroid hormones in disturbances of the nervous system. Key among these ®ndings was the clear statistical bias toward either men or women in the incidence and recovery from neurological damage and mental disorders. Additionally, new tools were developed which allowed the mapping of estrogen receptors outside of the brain regions responsible for reproduction. Collectively, the evidence has led to a growing appreciation that the positive impact of estrogen on neurite outgrowth and neuronal survival in the hypothalamus might have more generalized applicability than was previously widely recognized.
Until the late seventies and early eighties, soon after morphological sex dierences in the brain were ®rst recognized in birds and mammals, the possible eects of estrogen on areas of the nervous system outside of those regions speci®cally involved in reproduction were often either unrecognized or disregarded as being irrelevant. Basic studies in neuroscience typically used mixed sex groups until it was appreciated that this induced a high degree of variability into the results of speci®c experiments. After that time, most researchers elected to use exclusively males for their studies, because they considered that experimental designs which took into account female cyclicity were too cumbersome to attempt, unless, of course, the subject of study was a speci®c aspect of female physiology or behavior. Societal issues that allowed disregard for disorders more prevalent in women, beliefs that humans are less susceptible to hormonal in¯uences than other species, as well as extensive arguments within the medical community for biological vs cultural causation in psychiatric disturbances, may all have played a role in the traditional lack of appreciation of hormones as a possible positive in¯uence in neurological and mental disorders. Potentially important hormone-dependent sex dierences in speci®c disorders and in responses to therapeutic interventions were thus largely ignored. Although still controversial in some arenas, the idea that estrogen and other gonadal hormones may play a role in neuroprotection has gained general acceptance and is the subject of ever increasing investigation. A potential complication, but ultimate bene®t, in examining the therapeutic role of estrogen in neuroprotection comes from the development of selective estrogen receptor modulators (SERMS) that target one estrogen sensitive tissue over another; the speci®c actions of SERMS in the nervous system will need to be evaluated, but SERMS may ultimately be useful in targeting neuroprotective actions of estrogen analogs, while not activating neuroendocrine functions.
Although epidemiological and basic science studies point to estrogen as an important factor in neuroprotection, proving such a role in clinical studies is not simple, for several important biological reasons. The functions of estrogen are intimately associated with those of progesterone and androgen, making it dicult to consider each independently with respect to neuroprotection. Estrogen regulates expression of both progestin (Thornton et al., 1986; Warembourg et al., 1986; Blaustein et al., 1988; DonCarlos et al., 1989; Bethea et al., 1992) and androgen (Handa et al., 1986 (Handa et al., , 1996 DonCarlos, 1999a, 1999b) intracellular receptors, so that biologically relevant eects of progestin and androgen may depend on prior exposure to estrogen. Furthermore, testosterone is a precursor for estrogen synthesis, and the enzyme responsible for this conversion, aromatase, is expressed in the brain (Naftolin, 1994; Lephart, 1996; Celotti et al., 1997; Balthazart and Ball, 1998; Hutchison et al., 1999) . During development, steroid hormone exposure may permanently alter the susceptibility to speci®c neurodegenerative diseases or alter recovery of function from traumatic episodes so that estrogen may have dierent eects in females and males due to dierential sensitivity to the hormone. Genetic risk for certain diseases may be greater in males when genes on the X chromosome have an impact on the disease. Finally, because estrogen lowers cholesterol and alters immune function, the role of estrogen in neuroprotection may be indirect, through actions on other organs which then impinge upon the health of the brain.
A ®nal introductory comment is that the term neuroprotection refers not to a single phenomenon but rather encompasses a spectrum of independent processes. Estrogen directly promotes cell survival, promotes synaptic plasticity, and prevents axonal and dendritic pruning. Estrogen can also prevent malfunction of neurons by altering levels of neurotransmitters, neurotransmitter receptors, and second messengers. This regulation of neurotransmitter function can then, secondarily, promote cell survival and neurite branching. Thus, the protective eects of estrogen are multifaceted ( Fig. 1) . In this review, the primary, though not exclusive, focus is on the role of estrogen in cell survival.
Neuroprotective eects of estrogen

Clinical studies
Estrogen has been associated with a decreased risk, delayed onset and progression, or enhanced recovery from numerous traumatic or chronic neurological and mental diseases, some of which are discussed below. These span many dierent types of disease and trauma, ages, and hormonal status, and can be variously classi®ed as dysfunction due to abnormal development (dyslexia, autism), abnormal neurotransmitter systems (depression; anorexia/bulimia), disorders caused by trauma (stroke, epilepsy, head injury), or disorders caused by abnormal immune (multiple sclerosis) or cardiovascular (stroke, head injury) function. The etiology of some disorders that are slowed or alleviated by estrogen is unknown (Alzheimer's disease, Parkinson's disease, sleep disorders). Some of these disorders are sexually dierentiated in children, suggesting an eect of steroid hormones during development. Others present at times of altered hormonal status such as puberty, pregnancy or menopause, or increase with age. In the various sections below, selected examples of disorders and diseases for which there has been a preponderance of discussion or data suggesting a sex dierence or estrogenic component in protection are discussed. The speci®c cellular mechanisms involved in estrogen dependent neuroprotection are discussed in later sections. Fig. 1 . Mechanisms that may be involved in neuroprotection by estradiol. The hormone may directly aect cell survival or prevent cell death by acting on cell death cascades. In addition, estradiol may promote cell survival by the induction of axonal sprouting of injured axons, by augmenting regeneration of damaged neural connections and by promoting synaptic transmission.
Stroke
Stroke is a leading cause of mortality and morbidity in the population over middle age (reviewed in Paganini-Hill, 1995) . Estrogen is thought to protect against stroke in humans, but whether this occurs throughout life, and the precise mechanisms estrogen might use to provide protection, are unclear. Men and women do not dier with respect to the primary risk factors for stroke, which are age and high blood pressure. Men and women do dier, however, with respect to the incidence of stroke, with premenopausal women having fewer strokes and dierent types of strokes than observed in age matched men; after menopause, the incidence of stroke increases in women compared to age matched premenopausal women. Most strokes (80%) are due to cerebral infarct, the type of stroke most common in men. Subarachnoid hemorrhages are less common, but occur with higher frequency in women than in men (Kertesz and Benke, 1989; Paganini-Hill, 1995) . In part, these dierences appear to be due to the eects of endogenous estrogen on lowering of cholesterol levels and on vascular endothelium, protective eects that are lost in postmenopausal women. Dierences in the in¯ammatory response may also contribute to the sex dierences in response to infarct (Li et al., 1994) The observations from epidemiological studies that moderate exposure to exogenous estrogen may decrease the risk of stroke (discussed below), together with the ®nding that tamoxifen (an estrogen receptor antagonist) treatment confers increased risk for stroke in women (Gail et al., 1999) lend credence to the idea that estrogen plays a protective role in cerebrovascular disease. However, pregnancy and childbirth are associated with an increased risk of stroke. The National Institute for Neurologic Disorders and Stroke (1999) reported that the risk of ischemic stroke is nine times higher and hemorrhagic stroke 28 times higher during the ®rst 6 weeks of postmartum, but the cause is not known.
High dose oral contraceptives, such as the preparations used before the 1980s, were associated with increased risk for stroke in premenopausal women, but the preparations now in use contain less estrogen, and are not associated with any increased risk for either ischemic or hemorrhagic stroke (Petitti et al., 1996 (Petitti et al., , 1998 Chang et al., 1996) . Paganini-Hill (1995) reviewed epidemiological studies that assessed the impact of estrogen replacement therapy on the relative risk for stroke. Many of the reports are con¯icting; some have not demonstrated any eect of postmenopausal hormone use on stroke risk (eg, Petitti et al., 1998) . However, the majority of studies have shown that continued use of estrogen, and to a lesser extent, former use of estrogen, reduces the risk of stroke by an average of 50% (e.g. Paganini-Hill et al., 1988; Falkeborn et al., 1993; Longstreth et al., 1994) . Similarly, at least one estrogen receptor antagonist, tamoxifen, increases the risk of stroke (Gail et al., 1999) . A magnetic resonance imaging and neuropsychiatric study found a lower incidence of asymptomatic ischemic brain damage in postmenopausal women taking estrogen compared with those who did not, but no association between the extent of white matter damage and cognitive test results (Schmidt et al., 1996) . Since risk appears to depend on the type and amount of estrogen used, it is clear that clinical trials to determine the precise consequences of endogenous and exogenous steroid exposure in conferring the risk of stroke will need to be carefully designed. The potential negative in¯uences of estrogen or estrogen receptor antagonists may restrict the use of estrogen as a preventative measure for stroke to a particular cohort of women.
Earlier studies have reported that the retention of verbal abilities is better in female stroke victims than in male stroke victims (reviewed in Kertesz and Benke, 1989) , and that women experience a better recovery from aphasia than do men (Pizzamiglio et al., 1985) , possibly due to dierences in laterality or initial verbal uency. Subsequent studies have altered this view: although the incidence of infarct may be higher in men than in women, among stroke patients with similar lesion size and location, no clear-cut sex dierences exist in the frequency of aphasia (Kertesz and Sheppard, 1981; Kertesz and Benke, 1989; Hier et al., 1994) , or prognosis for recovery of verbal¯uency (Sarno et al., 1985; Schehter et al., 1985; Pedersen et al., 1995) . On other measures, such as contralateral spatial neglect, men fare better than women when the right hemisphere is damaged (McGlone et al., 1997) . Nevertheless, since basic science discoveries have pointed to the involvement of circulating and exogenous estrogen levels in the size of the lesion and recovery from experimentally induced stroke, estrogen may exert direct neuroprotective eects that limit damage to neurons following ischemia episodes in humans as well (see Section 2.2.2).
Alzheimer's disease
Alzheimer's disease aicts more women than men, has an earlier onset in women, and progresses more rapidly in women. Many epidemiological studies have pointed to the protective role of estrogen in Alzheimer's disease. One extensive clinical study assessing the protective role of estrogen in Alzheimer's disease was conducted by Paganini-Hill and Henderson (1996) . This study was based on postmortem follow-up reports of almost 4000 women who had answered a health survey that was administered, on average, 5 years before death. They found an inverse relationship between estrogen use and Alzheimer's disease; the risk of Alzheimer's disease decreased with increasing dose and duration of estrogen replacement therapy. Exogenous estrogen treatment appears to be the key, because there was no relationship between Alzheimer's disease and age at menarche or age at the last menstrual period, although higher body weight, and therefore presumably higher levels of estrogen due to formation in adipose tissue, conferred some decreased risk for Alzheimer's disease. Results of many other epidemiological studies are in agreement in demonstrating an inverse relationship between estrogen use and Alzheimer's disease (e.g. Tang et al., 1996; Yae et al., 1998; Costa et al., 1999; Slooter et al., 1999; Waring et al., 1999) , but most discuss the methodological diculties inherent in conducting and controlling large scale, survey based, studies and call for double blind analyses to be performed.
One of the earliest clinical trials assessing the potential impact of estrogen on Alzheimer's disease was a small pilot study of seven women who had been diagnosed with senile dementia of the Alzheimer's type (Fillit et al., 1986) . Low-dose estrogen therapy modestly improved cognitive function and mood in some of the women. The large prospective study of Henderson, Paganini-Hill and collaborators (Henderson et al., 1994) also showed that estrogen not only protects against the onset of Alzheimer's disease, but also helps to maintain the cognitive function of those women who already have Alzheimer's disease. The cognitive function of women with Alzheimer's disease who had received estrogen replacement therapy was well below non-demented control subjects, but better than the cognitive function of those Alzheimer's disease patients not taking estrogen. Subsequent case-control (Resnick et al., 1998) and retrospective (Costa et al., 1999) studies have con®rmed that estrogen protects postmenopausal women from cognitive deterioration. Double-blind studies will be the key to con®rming a clinically signi®cant role for estrogen in protection from Alzheimer's disease; the number of such studies is still low, and study sizes are small, but the ®ndings support the use of estrogen to delay the onset of Alzheimer's disease and slow its progression. In one double-blind study of 12 women with mild to moderate Alzheimer's disease, estrogen (0.05 mg/day of 17b estradiol, delivered via a skin patch), improved attention and verbal memory within the ®rst week of treatment, but the eects were temporary, and diminished once estrogen treatment was stopped (Asthana et al., 1999) . It is of interest that there was a trend to an inverse relationship between plasma levels of both IGF-I and IGF-binding protein 3 and verbal memory, given that IGF-I is generally neuroprotective (seè`N eurotrophins'', p. 45). Estrogen increased activation of cortical regions involved in verbal memory tasks during storage and retrieval of verbal material, without altering verbal or nonverbal performance, in postmenopausal women given estrogen treatment (1.25 mg/ day, oral dose, 21 days, double-blind) and assessed using functional magnetic resonance imaging.
The potential cellular mechanisms that may underlie estrogen's neuroprotective actions are discussed in Section 3, but a speci®c series of genetic ®ndings are worth mentioning here with respect to estrogen and Alzheimer's disease susceptibility. First, there is an apparent interaction between estrogen receptor, apolipoprotein E (ApoE) and deposition of amyloid in the neuritic plaques that are one of the neuropathological hallmarks of Alzheimer's disease (Fig. 2) . Some background regarding the role of ApoE and beta amyloid is necessary here: ApoE is produced by astrocytes and microglia (see also Section 3.2.3.1), is important to membrane repair and synaptic plasticity (Teter et al., 1999 and see Bales et al., 1999 for a discussion) and is thought to reduce clearance of amyloid beta . Amyloid beta is a component of neuritic plaques that may itself be neurotoxic. The expression of ApoE may in fact be necessary for production of the abnormal amyloid deposits, since transgenic mice that overexpress beta amyloid precursor protein and are also ApoE(À/À) produce no amyloid deposits, whereas amyloid deposits are frequent in ApoE(+/À) and ApoE(+/+) mice . There are three allelic variants encoding three protein isoforms of ApoE. Of these, the highest risk of Alzheimer's disease, particularly the late-onset form, is found in individuals who are homozygous for the ApoE epsilon 4 allelle on chromosome 19 (Henderson et al., 1995) . Estrogen may normally ward o damage due to ApoE induced abnormalities in amyloid precursor protein processing, as estrogen has been shown to reduce the production of the neurotoxic, insoluble beta amyloid (Jae et al., 1994; Chang et al., 1997; Xu et al., 1998a Xu et al., , 1998b . Exogenous estrogen reduces the risk of Alzhei- mer's disease in individuals who are either homozygous or heterozygous for the ApoE epsilon 4 allele (Tang et al., 1996) .
Although it has been hypothesized that estrogen protects against beta amyloid deposition via its antioxidant properties Bonnefont et al., 1998) , nuclear receptor mediated mechanisms also appear to be involved in estrogenic neuroprotection in Alzheimer's disease because estrogen receptor polymorphisms, as identi®ed by restriction fragment length polymorphism analysis as P or p alleles (PvuII-RFLP) or X and x (Xba I-RFLP) are also associated with dementia. The frequency of the P and X alleles for estrogen receptor were found to be higher in Alzheimer's disease patients and Parkinson's disease patients with dementia, but not in Parkinson's patients without dementia or in control subjects (Isoe-Wada et al., 1999) . One of the most important recent ®ndings, potentially of enormous predictive value, is a genetic interaction between polymorphisms for both the estrogen receptor and ApoE genes (Brandi et al., 1999; Isoe-Wada et al., 1999) . Brandi et al. (1999) calculated that the frequency of late-onset of Alzheimer's disease was seven fold greater in those individuals that are homozygous for ApoE epsilon 4 and ER-a PPXX.
Another important molecular association for estrogen in Alzheimer's disease involves expression of choline acetyltransferase (Fig. 2) . Cholinergic neurons in the basal forebrain degenerate in Alzheimer's disease patients (Whitehouse et al., 1981) . Correlative studies of choline acetyltransferase activity in biopsy specimens results of neuropsychological tests have demonstrated that the loss of choline acetyltranferase activity is correlated with the loss of cognitive function (Baskin et al., 1999) . Estrogen upregulates choline acetyltransferase in the rat brain (Luine, 1985) although it is not known whether this occurs in humans, nor is the potential mechanism involved clear, since immunocytochemical studies of the primate basal forebrain have found that estrogen receptor alpha immunopositive cells are rare and do not contain cholinergic markers (Blurton-Jones et al., 1999) .
Other neurotransmitter systems are also implicated in the etiology of Alzheimer's disease, and estrogen may be protective through its eects on these systems (Fig. 2) . For example, estrogen normalizes neuroendocrine responses to a serotonergic agonist in postmenopausal women (Halbreich et al., 1995) and may decrease aective disorders via estrogen induced decreases in the G proteins that couple serotonin receptors to intracellular signaling molecules (Raap et al., 2000) or via alterations in serotonin transporter expression (McQueen et al., 1997) . Depression is one of the early symptoms of Alzheimer's disease; abnormalities of serotonergic function have been proposed to be causal in both disorders (e.g. Meltzer et al., 1998) .
In conclusion, the etiology of Alzheimer's disease is clearly multifactorial, but for many of the factors, estrogen may provide protective value, and estrogen receptor malfunction may increase risk. Considerable support is therefore available for the use of estrogen replacement therapy to decrease vulnerability to Alzheimer's disease, and in those individuals who are already diagnosed with Alzheimer's disease, to maintain cognitive function (see note added in proof).
Schizophrenia
The overall lifetime risk for schizophrenia is not dierent between men and women (reviewed in Lindamer et al., 1997; Seeman, 1997; Canuso et al., 1998; Hafner et al., 1998) . However, the age of onset, the severity of symptoms, and the type of symptoms are dierent in men and women and point to a protective role for estrogen in schizophrenia. Schizophrenia generally occurs slightly later in women and, until menopause, has a less severe course in women than in men. Moreover, although the peak age of onset for schizophrenia is generally late adolescence to early adulthood in both men and women, a second cohort of women develops schizophrenia at the onset of menopause, as estrogen levels begin to¯uctuate and decline (Lindamer et al., 1999) . Numerous correlational studies show that the severity of psychiatric disturbance decreases with increasing estradiol levels during the menstrual cycle and during pregnancy. Preliminary results from limited clinical trials with hormone replacement therapy provide further evidence that estrogen is protective, and decreases a speci®c subset of schizoid symptoms.
Abnormalities of brain maturation may lead to structural abnormalities that underlie schizophrenia, and sex hormone exposure during development may therefore contribute to the sex dierences in schizophrenia (Gruzelier, 1994; Nopoulos et al., 1997) . There are con¯icting results as to whether sex dierences actually exist in the brain structural abnormalities associated with schizophrenia as would be expected if sex hormone exposure during development contributes to the greater vulnerability of the male brain. Two carefully controlled, and similar magnetic resonance imaging (MRI) studies demonstrate these con¯icting results. In the ®rst, male and female hospitalized schizophrenics had similar decreases in cortical gray matter and similar ventricular enlargement compared with healthy, sex-matched controls (Lauriello et al., 1997) . In the second study, the cortical gray matter was decreased and the ventricles were enlarged to a greater extent in male schizophrenics compared with female schizophrenics when each group was compared to its healthy sex and age matched control group (Nopoulos et al., 1997) ; these investigators emphasized that the sex dierence is one of severity of the structural abnormality, rather than pattern. Dierent conclusions have also been reached regarding sex dierences in the extent of cognitive impairment in schizophrenic patients, with some studies concluding that male patients are more impaired than female patients and others concluding that any sex dierences in the degree of impairment are minimal .
Modulation of dopaminergic function may underlie the protective eects of estrogen. The dose of neuroleptic drugs required to treat women with schizophrenia is lower than that for men, at least at the younger ages (reviewed in Di Paolo, 1994 and in Canuso et al., 1998) . Estrogen may act essentially as an endogenous neuroleptic since estrogen seems to enhance the actions of dopamine antagonists in animal models (Hafner et al., 1991) . Preliminary results suggest that dopamine receptor anity is lower in some brain regions in women than in men (Pohjalainen et al., 1998) .
In addition to circulating estrogen, a genetic component may also contribute to sex dierences in the onset and course of schizophrenia (Hafner et al., 1998) . A case has been made by Gruzelier (1994) that sex chromosomes may contribute to the observed dierences in schizophrenia in men and women, particularly those sex dierences in the symptoms thought to arise from abnormalities of brain lateralization. Structural abnormalities in the temporoparietal region and cognitive de®cits have been observed in women with Turner's syndrome, who have either a karyotype XO or a mosaic XO karyotype. The hormonal de®ciencies in both Turner's syndrome groups are similar, but the cognitive and structural impairments of the mosaic XO women are less severe than those of full XO women. The structural abnormalities and patterns of cognitive asymmetry observed in Turner women and in Kleinefelter's (XXY) men are consistent with some of the abnormalities observed in schizophrenia. Trinucleotide repeats confer some genetic risk for schizophrenia, particularly the childhood onset form of the disease, and are more common in males (Burgess et al., 1998) .
Experimental studies
In vitro evidence
For many years, it has been known that estradiol is a factor that promotes viability and survival of neurons in primary neuronal cultures. Estradiol is one of the components that is added to serum-free de®ned culture media for neuronal cultures (Faivre-Bauman et al., 1981) . Addition of 17b-estradiol to de®ned culture media increases the viability, survival and dierentiation of primary cultures from dierent neuronal populations, including hypothalamic neurons (Chowen et al., 1992; DuenÄ as et al., 1996) , amygdala neurons (Arimatsu and Hatanaka, 1986) , neocortical neurons (Brinton et al., 1997) or hippocampal neurons (Sudo et al., 1997) . In addition, in vitro neuroprotective eects of 17b-estradiol from cell death induced by a variety of stressors are well documented (Table 1 ). The hormone increases survival of cultured dorsal root ganglion neurons deprived of nerve growth factor (Patrone et al., 1999) , primary mesencephalic cultures exposed to glutamate, superoxide anions or hydrogen peroxide (Sawada et al., 1998) and hippocampal cultures exposed to NMDA (Weaver et al., 1997) . Many studies using primary cortical cultures have shown that estradiol prevents neuronal death induced by dierent stimuli such as iron glutamate toxicity (Singer et al., 1996b; Zaulyanov et al., 1999) , AMPA toxicity (Zaulyanov et al., 1999) , the pro-oxidant hemoglobin (Regan and Guo, 1997) , anoxia (Zaulyanov et al., 1999) , cytochrome oxidase inhibitor sodium azide, kainate or NMDA (Regan and Guo, 1997) . Other studies have used neuronal cell lines to demonstrate the neuroprotective eects of estradiol. For instance, 17b estradiol protects NT2 neurons, PC12 cells and mouse neuroblastoma (Neuro 2a) cells from H 2 O 2 or glutamate induced cell death (Singer et al., 1998; Bonnefont et al., 1998) , SK-N-SH human neuroblastoma cells from serum deprivation (Green et al., 1997) , hippocampal HT 22 cells from lipid peroxidation and B 103 cells (MookJung et al., 1997) , PC12 cells and Neuro 2a cells (Bonnefont et al., 1998 ) from neurotoxic eects of beta amyloid. This long, but not exhaustive, list of studies reveals that the neuroprotective eects of estradiol have recently received considerable attention. These in vitro studies have provided important insights into the possible mechanisms involved in the in vivo neuroprotective eects of estrogen that will be discussed below. 
In vivo evidence
In addition to the extensive evidence for neuroprotective eects of estradiol in vitro, there is now abundant evidence for neuroprotection by the hormone in dierent experimental models in vivo (Table 1 ). In agreement with clinical ®ndings, several animal studies have shown that estrogen improves memory performance in females. Estrogen replacement improves working memory in ovariectomized rats (Simpkins et al., 1997a; Bimonte and Denenberg, 1999; Fader et al., 1999) but does not aect reference memory performance (Fader et al., 1999) . In ovariectomized mice, tonic estrogen replacement therapy improves two dierent types of memory processes that depend on striatal and hippocampal memory systems (Rissanen et al., 1999) . Estrogen treatment has been shown to improve memory performance in male rodents as well. Estradiol treatment of male rats partially compensates for the learning de®cits and deterioration of memory induced by the intracerebroventricular administration of streptozotocin (Lannert et al., 1998) . These ®ndings suggest that estrogen may have a general enhancing eect on neural activity and may be involved in the normal maintenance of neural function. Therefore, the decline in estrogen levels that occurs with age may be the cause of the increased rate of age-related cognitive impairments in female rodents compared to males (Markowska, 1999; Frick et al., 2000) . The decrease in estrogen levels with age in females may increase the risk of neurodegenerative disorders since the hormone has been shown to protect neurons in vivo from dierent lesion paradigms.
Experimental forebrain ischemia has been one of the models used to test the neuroprotective eect of estradiol in vivo. The protective eects of estrogen in this model have been documented in rats (Simpkins et al., 1997b; Dubal et al., 1998; Pelligrino et al., 1998; Zhang et al., 1998; Wang et al., 1999; Rusa et al., 1999) , mice (Culmsee et al., 1999) and gerbils (Sudo et al., 1997; Chen et al., 1998) . Simpkins et al. (1997b) have shown that pretreatment with 17b-estradiol reduces animal mortality and ischemic area in ovariectomized rats after middle cerebral artery occlusion. Interestingly, the isomer 17a was able to reduce mortality and to reduce the ischemic area as well. Both systemic and intracerebral administration of 17b-estradiol were protective in this model. In the study of Dubal et al. (1998) , systemic estradiol pretreatment signi®cantly reduced overall infarct volume compared with oil injected controls. Sudo et al. (1997) tested the eect of estradiol administered into the lateral cerebral ventricle. These authors have shown that 17b-estradiol infused into the lateral cerebral ventricle prevents ischemia-induced learning disability and neuronal loss at early stages after transient forebrain ischemia in gerbils (Sudo et al., 1997) . Chen et al. (1998) have also found a neuroprotective eect of 17b-estradiol on CA1 hippocampal cells after ischemia in gerbils. Furthermore, 17b-estradiol decreases the expression of betaamyloid precursor protein mRNA following focal ischemia in ovariectomized female rats .
Another experimental model of great interest is injury of the nigrostriatal system. Estrogen has neuroprotective properties against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in the nigrostriatal dopaminergic system. Estradiol treatment prevents reductions in dopamine concentrations in the striatum of ovariectomized mice (Dluzen et al., 1996a (Dluzen et al., , 1996b Dluzen, 1997 Dluzen, , 2000 Callier et al., 2000) . Furthermore, 17b-estradiol reduces the dyskinetic eect of MPTP in cynomolgus monkeys, while 17a-estradiol is ineective (Gomez-Mancilla and Bedard, 1992) . Basal forebrain cholinergic neurons may also be protected by estradiol, since Rabbani et al. (1997) found that administration of 17b estradiol to ovariectomized rats attenuated the decrease of choline acetyltransferase immunoreactive neurons in the medial septum after ®mbria lesion-induced degeneration.
The neuroprotective eect of estradiol on the hilus of the dentate gyrus has been investigated after systemic administration of kainic acid, a widely used experimental model of epilepsy and neurodegeneration. Kainic acid treatment results in the appearance of chronic, spontaneous, recurrent seizures and neurodegenerative changes in the dentate gyrus, including loss of somatostatinergic interneurons in the hilus. Systemic administration of a low dose of kainic acid (7 mg/kg b.w.) results in mild behavioral symptoms and a loss of no more than 25±40% of Nissl-stained hilar neurons. Administration of 17b-estradiol to ovariectomized rats is able to prevent this partial hilar neuronal loss (Azcoitia et al., 1998) . Of critical importance with regard to the normal neuroprotective eects of estrogen, the eect of kainic acid on hilar neurons in intact female rats is dierent depending on the day of the estrous cycle on which the neurotoxin is injected. No signi®cant neuronal loss is observed when kainic acid is injected on the morning of estrus. In contrast, there is a signi®cant loss of hilar neurons when kainic acid is injected in the morning of proestrus as well as when it is injected into ovariectomized rats ). These ®ndings demonstrate that the natural uctuation of ovarian hormones during the estrous cycle may in¯uence the vulnerability of hilar neurons to excitotoxicity.
The possible neuroprotective eect of estrogen has been tested in male rats as well. Estradiol treatment results in an increase in the rate of regeneration of axotomized facial motoneurons of male hamsters, an eect also induced by testosterone and by the non aromatizable androgen dihydrotestosterone (Tanzer and Jones, 1997) . Toung et al. (1998) have found that either acute or chronic administration of 17b-estradiol protects the male rat brain after experimental stroke using 2 h of reversible middle cerebral artery occlusion. Cortical and caudate infarct volumes are reduced by acute and chronic hormonal treatments. Toung et al. (1998) and Kujawa and Jones (1991) also studied the eect of castration on neural response to injury. Castration did not alter ischemic outcome whereas estrogen replacement reduced infarct volume in castrated animals. Similarly, the rate of regeneration following facial nerve axotomy was not dierent in intact vs. castrated male hamsters (Kujawa and Jones, 1991) . Both studies suggested that circulating testosterone levels are insucient to supply prohormone to provide neuroprotective levels of estrogen in vivo. Estrogen also has neuroprotective properties against MPTPinduced neurotoxicity in the nigrostriatal dopaminergic system of castrated males, preventing reductions in corpus striatum dopamine concentrations (Dluzen et al., 1996a (Dluzen et al., , 1996b . However, the interpretation of the neuroprotective eects of estrogen in male animals is complicated by the possible in¯uence of androgens.
Clinical data show that women recover better than men after traumatic brain injury (Groswasser et al., 1998) . In agreement with this observation, and with those commented on in Section 2.1.1 in several experimental neural lesion models male animals are more vulnerable than female animals. For instance, female rats have better stroke outcomes after vascular occlusion than males (Li et al., 1996; Alkayed et al., 1998; Zhang et al., 1998) , while male rats show stronger memory de®cits after entorhinal cortex lesions than females (Roof et al., 1993a) . Sex dierences have been also observed in striatal dopaminergic neurotoxicity in mice (Miller et al., 1998) . Two neurotoxicants tested, MPTP and methamphetamine (METH), resulted in a greater dopamine depletion in males than in females (Yu and Wagner, 1994; Miller et al., 1998) . However, in a study in which the susceptibility of the cholinergic septo-hippocampal pathway to the neurotoxic eect of ethylcholine aziridinium (AF64A) was investigated in the rat, Hortnagl et al. (1993) found that adult female rats in general, and particularly females on proestrus, were more susceptible to the neurotoxic action of submaximal doses of AF64A than age-matched male rats.
Sex dierences in outcome after dierent forms of brain lesions may be due in part to estrogen, progesterone or testosterone. Neuroprotective eects of progesterone will not be covered in depth in this review, except to mention that several studies have shown that progesterone may reduce cerebral damage after dierent forms of insults (Stein and Fulop, 1998) . For instance, progesterone facilitates cognitive recovery, reduces secondary neuronal loss and protects against lipid peroxidation following traumatic brain injury in rats (Roof et al., 1993b (Roof et al., , 1994 (Roof et al., , 1997 Asbury et al., 1998) and reduces neuronal loss in the cat hippocampus after acute cerebral ischemia (GonzalezVidal et al., 1998) . Sex dierences in the response to brain injury may also be the consequence of a damaging eect of testosterone. While testosterone is a survival factor for axotomized motoneurons and promotes motor axon regeneration (Yu, 1989; Jones, 1993; Kujawa et al., 1993; Kelly, 1996, 1997; Kinderman et al., 1998) , the hormone may have a negative eect for other injured neuronal populations. For instance, testosterone increases the lesion size induced by middle cerebral artery occlusion in castrated male rats, while estradiol treatment reduces the ischemic area (Hawk et al., 1998) . Nishino et al. (1998) have used systemic intoxication with 3-nitropropionic acid, a succinate dehydrogenase inhibitor, to induce selective histological lesions in the striatum. These lesions are associated with motor symptoms and are highly sex-dependent. Males are more susceptible than females. Gonadectomy has little eect on males but enhances the vulnerability of females to the substance. Furthermore, testosterone increases the vulnerability while estrogen replacement suppresses the vulnerability in ovariectomized rats (Nishino et al., 1998) .
The deleterious eect of testosterone in some experimental models of brain injury may be secondary to its conversion to dihydrotestosterone and its action on androgen receptors. However, it is important to consider the possibility that the negative eect of testosterone may be the consequence of its conversion to estradiol by local aromatase activity. It is well known that high levels of estradiol may be neurotoxic for some hypothalamic neurons (Brawer et al., 1978; Desjardins et al., 1995) , and the idea cannot be excluded that high local levels of estrogen may be neurotoxic for other neuronal populations as well. This would mean that high local levels of estrogen may be deleterious while low local levels of estrogen may provide neuroprotection. Therefore, it is important to determine the concentration of estradiol that may exert a neuroprotective eect in vivo.
Several studies have assessed whether the neuroprotective eects of estrogen in dierent lesion paradigms are dose-dependent. For example, the eect of estradiol in preventing ischemic damage is dose-dependent. When infused at a dose of 0.25 mg/day, estradiol decreased ischemic damage in gerbils, whereas a dose of 1.25 mg/day was ineective and even increased mortality of experimental animals (Sudo et al., 1997) . Dierent results have been obtained by Chen et al. (1998) . According to these authors, high doses of 17b-estradiol improve the histological outcome after transient forebrain ischemia in hippocampal CA1 pyramidal cells of gerbils, whereas low doses of estradiol do not have any protective eect. In rats, chronic low-dose estradiol treatment (0.1 mg/kg per day) has a bene®cial eect on cortical cerebral blood¯ow during forebrain ischemia. However, the bene®t is lost with a dose of 0.5 mg/kg per day or with higher doses (Pelligrino et al., 1998) . Dubal et al. (1998) have found neuroprotective eects of low (10 pg/ml in plasma) and high (100 pg/ml in plasma) estradiol levels in the rat cerebral cortex after ischemia. In another study, long term treatment with 17b-estradiol implants of 25 mg (resulting in 20 pg/ml in plasma) reduces stroke injury in ovariectomized females while implants of 100 mg (46 pg/ml in plasma) do not (Rusa et al., 1999) . These studies show some discrepancies concerning the optimal dose of estradiol needed to obtain a neuroprotective eect in vivo. This may be in part because dierent brain areas require dierent optimal hormone concentrations. The severity of the lesion and the route of administration may also be an important determinant in the hormone concentration required to counterbalance the damage. In spite of the discrepancies, most studies show a neuroprotective eect at low estradiol doses. This ®nding is relevant to the mechanism of action, as discussed below.
Mechanisms of neuroprotection by estradiol
Peripheral versus local eects
The possible neuroprotective mechanisms of estradiol may be divided into two basic groups: local and peripheral, local eects being those exerted directly in the nervous system and peripheral eects being those exerted in other tissues, such as the systemic regulation of metabolism and the cardiovascular system. Hormonal eects on the cardiovascular system may facilitate brain irrigation and therefore may protect neurons and glia from ischemia. Peripheral metabolic and cardiovascular eects of the hormone will not be considered in this review. Among the local eects, it is important to distinguish those mediated by the activation of estrogen receptors and those that are not dependent on the actions of estrogen receptors. Furthermore, the local eects of estradiol may be divided into those exerted on neurons and those exerted on glial cells or other cellular elements of the nervous system. These dierent local eects of estrogen will be considered in the following sections.
Local eects 3.2.1. Mechanisms independent of the transcriptional activation by estrogen receptors
Among the local hormonal eects, there is a strong line of evidence supporting mechanisms independent of estrogen receptor activation. Some in vitro studies have shown that high, non-physiological doses of estradiol are neuroprotective while low doses of estradiol, optimal to induce estrogen receptor-mediated gene transcription, are not. For instance, 133 nM 17b-or 17a-estradiol but not 1.3 nM 17b-estradiol protect primary rat cortical neuronal cultures from anoxiareoxygenation, glutamate, or AMPA toxicity (Zaulyanov et al., 1999) . Furthermore, protective eects of estradiol have been documented in neuronal cell lines lacking functional estrogen receptors or in the presence of estrogen receptor antagonists. Both 17a and 17b-estradiol provide protection of SK-N-SH human neuroblastoma cells from serum deprivation and the neuroprotective eect was only partially reversed by the estrogen receptor antagonist tamoxifen. This ®nding suggests that estrogen may have neuroprotective eects that are not mediated by estrogen receptor signaling (Green et al., 1997) , although another possibility is that tamoxifen exerted partial agonist activity in these cells. A neuroprotective eect of estradiol independent of estrogen receptors has been demonstrated in the HT-22 murine neuronal cell line. 17b estradiol and 17a estradiol protect HT-22 cells from beta-amyloid peptide toxicity, in spite of the fact that these cells lack functional estrogen receptors .
Neuroprotection independent of estrogen receptors has been observed in primary neuronal cultures as well. The estrogen receptor antagonist, tamoxifen, does not interfere with the neuroprotective eects of 17b-estradiol against NMDA-induced neuronal death in rat hippocampal cultures (Weaver et al., 1997) . Furthermore, neither estrogen receptor antagonists nor protein synthesis inhibitors block estrogen-induced protection against glutamate neurotoxicity in mesencephalic cultures (Sawada et al., 1998) . In addition, estrogen receptor antagonists do not block the protective eects of estradiol against pro-oxidants in rodent and chick neuronal cultures (Behl et al., 1995 (Behl et al., , 1997 Regan and Guo, 1997; Culmsee et al., 1999; Moosmann and Behl, 1999) .
One of the most popular views to explain the neuroprotective eects of the hormone is related to the endogenous antioxidant capacity of the estradiol molecule (Fig. 3) . It is very well documented that estradiol has antioxidant properties and suppresses the oxidative stress in neurons and neuronal cell lines induced by hydrogen peroxide, superoxide anions and other pro-oxidants (Behl, 1999; Behl et al., 1995 Behl et al., , 1997 Mattson et al., 1997; Bonnefont et al., 1998; Sawada et al., 1998; Behl and Holsboer, 1999; Calderon et al., 1999; Culmsee et al., 1999; Kruman et al., 1999; Moosmann and Behl, 1999; Behl and Manthey, 2000) . Both 17a and 17b estradiol have similar antioxidant eects (Behl et al., 1995 (Behl et al., , 1997 Calderon et al., 1999; Bonnefont et al., 1998) .
Supraphysiologic concentrations of estradiol have a clear antioxidant eect in vitro. For instance, 17b-estradiol, 17a-estradiol and some estradiol derivatives can prevent intracellular peroxide accumulation and degeneration of cultured neurons and clonal hippocampal cells. The antioxidant activity of estrogens is observed at very high concentrations (10 À5 M), is dependent on the presence of the hydroxyl group in the C3 position on the A ring of the steroid molecule and is independent of an activation of the estrogen receptors (Behl et al., 1995 (Behl et al., , 1997 Culmsee et al., 1999; Moosmann and Behl, 1999; Behl and Manthey, 2000) . A similar ®nding has been reported by Regan and Guo (1997) , showing that 17b-estradiol at a dose of 10 mM results in a complete prevention of neuronal loss in murine cortical cultures due to prolonged exposure to the pro-oxidant hemoglobin. Most of this eect persisted despite concomitant treatment with the antiestrogen ICI 182, 780 or the protein synthesis inhibitor cycloheximide (Regan and Guo, 1997) .
Lipid peroxidation of membrane and fatty acids represents an important endpoint of pro-oxidative cell damage. Keller et al. (1997) and Vedder et al. (1999) have used iron, one of the most powerful initiators and propagators of lipid peroxidation, to determine the role of estradiol on lipid peroxidation. These authors found that 17b-estradiol decreases ironinduced lipid peroxidation in rat brain homogenates , rat cortical synaptosomes (Keller et al., 1997) , hippocampal HT 22 cells and primary neocortical cultures . However, it is unlikely that this mechanism will be relevant clinically for the neuroprotective eects of estradiol, since very high concentrations of the hormone are necessary to reduce lipid peroxidation .
In conclusion, it is clear that estradiol has antioxidant properties and may protect neurons from oxidative stress. However, these eects are observed with high supraphysiologic concentrations of the hormone and their relevance to the neuroprotective eects of estradiol in vivo is questionable, particularly in a clinical sense. It should be noted, however, that it is unknown what the local concentrations of the hormone may be in a focal injured area in the brain. The recent discovery that aromatase expression is induced de novo in reactive astrocytes in injured brain areas opens the possibility that injury induced increases in aromatase synthesis, and therefore increased local estrogen formation, may result in high local estrogen levels in the proximity of damaged neurons.
In addition to anti-oxidant eects, estradiol may use other possible neuroprotective mechanisms that are independent of nuclear estrogen receptor activation (Fig. 3) . Estradiol may interact with estrogen binding sites in the plasma membrane (Ramirez and Zheng, 1996) and may have many dierent rapid eects on neuronal excitability (Moss and Gu, 1999) and neuronal transmission (Bicknell, 1998) . In rat hippocampal cultures estradiol may protect neurons from excitotoxicity by having direct membrane actions (Weaver et al., 1997) . The neuroprotective eect of 17b-estradiol is dose-dependent, with an EC50 of about 7 mM. In this model, 17a-estradiol does not reduce NMDA-induced neuronal death, indicating that the neuroprotective eect of estradiol is stereospeci®c. However, tamoxifen does not interfere with the neuroprotective eect, suggesting that estrogen receptors are not required for neuroprotection (Weaver et al., 1997) . Since both aand b-estradiol should have similar abilities to scavenge free radicals and since 17b-estradiol rapidly and reversibly inhibits the NMDA-induced current of cultured neurons, Weaver et al. (1997) conclude that the neuroprotective eect of the hormone may be a consequence of direct inhibition of NMDA receptor function. The neuroprotective eects of the hormone may be in part related to the modulation of neurotransmitters. For instance, estradiol may protect the nigrostriatal system by the regulation of dopamine release and via the inhibition of dopamine uptake by decreasing the anity of the transporter for dopamine (Disshon and Dluzen, 1997; Disshon et al., 1998; Dluzen, 2000) . Neuroprotective eects that involve hormonal activation of intracellular signaling pathways via G proteins (Moss and Gu, 1999; Raap et al., 2000) , extracellularly regulated kinases (see Section 3.2.3.3), phosphorylation of the cAMP response element binding protein (Zhou et al., 1996; Murphy and Segal, 1997; Panickar et al., 1997; Watters and Dorsa, 1998; Fig. 3 . Summary of mechanisms independent of the activation of nuclear estrogen receptors that may be involved in estrogen-induced neuroprotection. 1, Estrogen may act on unidenti®ed membrane sites and activate membrane associated signaling cascades that result in neuroprotection. The membrane-associated signaling may involve modi®cations in protein phosphorylation and modi®cations in the levels of intracellular signals such as cAMP and calcium. Alternatively, membrane related signaling cascades may result from the interaction of estradiol with putative membrane estrogen receptors (see Fig. 4 ). 2, Estradiol may act as an antioxidant. 3, Estradiol may aect neurotransmitter receptors, such as glutamate receptors, and regulate ionotropic and metabotropic activity. Walton and Dragunow, 2000) , and alterations in intracellular calcium levels (Beyer and Raab, 1998; PozzoMiller et al., 1999) should still be explored in detail.
3.2.2. Mechanisms mediated by the activation of estrogen receptors and gene transcription 3.2.2.1. Estrogen receptor mediated transcription in the nervous system. Many, though not all, of the physiological eects of estrogen are mediated through binding to estrogen receptor (ER) proteins. Like other members of the steroid receptor superfamily, estrogen receptors are ligand-activated transcription factors that are expressed in speci®c regions within target areas of the nervous system and other estrogen-sensitive organs. Until 1996, it was thought that only one estrogen receptor existed, but in that year and the next, two surprising discoveries indicated the presence of more than one estrogen receptor and greatly stimulated the ®eld of estrogen receptor research. The ®rst surprise came from accumulated evidence that, contrary to expectations, disruption of the estrogen receptor gene in mice did not disrupt all estrogen dependent functions; in the estrogen receptor knock out mice, residual levels of estrogen binding were present in several brain region and estrogen induced expression of progesterone receptor, an estrogen-dependent gene (Shughrue et al., 1997a (Shughrue et al., , 1997c . This research team concluded that, since the conventional ER had been disrupted, a variant form of ER might be present.
The second surprise discovery, also announced in the spring of 1996, was that a new estrogen receptor protein had been cloned (Kuiper et al., 1996) . With this ®nding, the conventionally de®ned ER was designated estrogen receptor-a (ER-a), and the new one was named ER-b. ER-b mRNA was rapidly identi®ed in numerous tissues, including the adult rat brain where it was found in a distribution that overlaps that of ER-a in some regions, but in other regions is quite distinct, as discussed below. Multiple splice variants of ER-b have been identi®ed, adding another layer of complexity to estrogen signal transduction (Petersen et al., 1998; Hanstein et al., 1999) . Of these splice variants, ER-b1 is probably the only variant with sucient abundance and anity for estrogenic ligands to exert important neural eects, although alterations in splicing following neural damage cannot yet be ruled out.
ER-a and ER-b share a structure that is similar to that of all members of the nuclear hormone receptor superfamily, and have highly homologous amino acid sequences in some domains, particularly the DNAbinding domain (Kuiper et al., 1996) . Both have an activation function domain in the amino terminus (AF-1), a central DNA binding domain and a carboxy terminus ligand binding domain, in which a second activation function (AF-2) resides. In vivo, estrogen receptors exist in association as part of an oligomeric protein complex that includes heat shock proteins and immunophilins (Tsai and O'Malley, 1994) . Upon binding to ligand, or following ligand-independent activation, estrogen receptors partially dissociate from this oligomer, and estrogen receptors form homo-and hetero-dimers (Cowley et al., 1997; Pettersson et al., 1997) that then bind to speci®c DNA sequences in target genes. The speci®c DNA sequences, termed estrogen response elements (EREs), are located in the promoter region of estrogen responsive genes, and in¯uence the rate of gene transcription. Although characteristically formed by inverted repeat sequences, functional analyses of individual genes are necessary to identify EREs, because some estrogen response elements are formed by half-palindromic ERE-like motifs with a few mismatched base pairs (Donaghue et al., 1999; Aumais et al., 1996; Kato et al., 1992) . For instance, promoter analyses have failed to identify perfect palindromic EREs in the promoter region of the mammalian ER-a gene (e.g. Donaghue et al., 1999 ; but see Le Drean et al., 1995 in trout and Lee et al., 1995 in frog) , but half-ERE sites with one or a few mismatched base pairs are frequent, and may allow a functional estrogen response. Putative EREs have been identi®ed in the promoter region of multiple genes that are both essential to normal brain function and implicated in brain disorders. Among these are the genes encoding choline acetyltransferase , the GABA transporter GAT-1 (Herbison et al., 1995) , a1a-adrenergic receptor , preproenkephalin (Zhu and Pfa, 1995) , oxytocin (Adan et al., 1993; Bale and Dorsa, 1997; Young et al., 1996) , somatostatin (Xu et al., 1998a , Xu et al., 1998b , galanin (Ko¯er et al., 1995; Corness et al., 1997) , glial ®brillary acidic protein (Stone et al., 1998b ), brain-derived neurotrophic factor (Sohrabji, et al., 1995) , transforming growth factor-alpha (El-Ashry et al., 1996) , Fos (Weisz and Rosales, 1990) , Myc (Dubik and Shiu, 1992) , cyclin D1 (Sabbah et al., 1999) and Bcl-2 (Teixeira et al., 1995) .
The ®nding of a new estrogen receptor subtype generated intense interest because of the underlying assumption that ER-a and ER-b would regulate dierent target genes. Tissue speci®c expression and dierences in the ratio and regulation of these two receptor subtypes may contribute to the wide diversity of tissue speci®c eects that occur in response to estrogen. The genes that are exclusively regulated by ER-a versus -b are unknown, in part because attempts to identify unique ligands and antagonists have not yet led to huge success. However, in addition to dierences in the distribution of the two receptor subtypes, dierences in the impact on the nervous system of ER-a versus ER-b knockouts have already been identi®ed; for example, ER-a knockout mice are virtually incapable of masculine reproductive behaviors (Ogawa et al., 1997 (Ogawa et al., , 1998 ) and ER-a knockout females did not display sexual receptivity , whereas reproductive behavior in ER-b knockouts appears to be essentially normal (Ogawa et al., 1999) . It is not yet known whether the neuroprotective eects are mediated through only one or both of these receptor subtypes or their splice variants.
During the last ®ve years, a wealth of new information has accumulated on the mechanisms underlying estrogen receptor dependent gene activation. For example, it is now known that estrogen receptors interact with the basal transcriptional machinery through complex interactions with other transcription factors and with identi®ed coactivators and adapter proteins (reviewed in Horwitz et al., 1996) which also remodel chromatin. These coactivators and adapter proteins may be present in limiting amounts and may impart transcriptional speci®city. Sequences within coactivator proteins, such as the nuclear receptor interaction box, may also stabilize the binding of agonists to ER, eectively increasing the level of functional estrogen and modulating temporal aspects of estrogen action by profoundly slowing (over 50-fold in cell free dissociation assays) the dissociation rate of estrogen agonists (Gee et al., 1999) . The eects of speci®c peptide sequences within these coactivators appear to interact with some ER subtype speci®city. Another coactivator that may be important to estrogen action is the androgen receptor associated protein designated ARA-70 (Yeh et al., 1998) . ARA-70 not only increases the ecacy of androgen induced AR transcriptional activity, but also allows estradiol to act as a ligand for androgen receptors, increasing AR transcriptional activity by up to 30-fold. Androgen receptors are expressed at moderate to high levels in many cells in regions that have been shown to bene®t from estrogen's neuroprotective actions, including the hippocampal formation (Kerr et al., 1995) , and the cerebral cortex (Simerly, 1990; Puy et al., 1995; Finley and Kritzer, 1999; McAbee and DonCarlos, 1998) . Thus, some of the neuroprotective actions of estrogen may be mediated via estrogen's binding to androgen receptors, although whether ARA-70 is expressed in the nervous system has not been con®rmed. In addition to interacting with estrogen response elements and possibly androgen response elements, estrogen receptors are able to aect transcriptional responses to other transcription factors, such as Jun and Fos at AP-1 sites (Paech et al., 1997) , perhaps through protein-protein interactions that do not rely on binding to an estrogen response element (Webb et al., 1999) . Results from molecular studies, largely carried out in cell culture, will need to be veri®ed in vivo, and in speci®c tissues, to determine whether phenomena such as heterodimerization, crossinterference of steroid receptors, and ERE independent transactivation constitute important, physiologically relevant mechanisms for estrogen signal transduction. It will be of critical interest to determine which speci®c coactivators or adapter proteins are expressed in the nervous system and whether their expression and regulation can be manipulated to enhance the neuroprotective eects of estrogen.
In addition to estrogen receptors acting as transcription factors within nuclei, there is increasing and very exciting evidence that estrogen receptors may mediate the eects of estrogen via interaction with intracellular signaling cascades (e.g. Lagrange et al., 1996 Lagrange et al., , 1997 Mermelstein, 1996; Singer et al., 1999; Singh et al., 1999; Toran-Allerand, 1996; Kelly et al., 1999 ; see also Section 3.2.3.3). Kelly, Ronnekliev and colleagues (Lagrange et al., 1996 (Lagrange et al., , 1997 Kelly et al., 1999) have established that estradiol can uncouple GABA-B and mu-opioid receptors from potassium channels via activation of protein kinase A and C. Estrogen activates mitogen-activated protein kinase (MAPK) and B-ras , an eect that is involved in the ability of estrogen to protect against glutamate induced nerve cell death (Singer et al., 1999) . G proteins are also activated by estrogen in the striatum, an area where membrane receptors have been hypothesized to exist (Mermelstein et al., 1996; Becker, 1999 and see discussion below). All of these eects are rapid and depend on the presence of estrogen receptor (or a putative membrane receptor, in the case of the striatum) but not on protein synthesis. These very exciting ®ndings of convergent pathways for estrogen receptor Fig. 4 . Summary of mechanisms of neuroprotection dependent on the activation of estrogen receptors. Estradiol may bind to putative estrogen receptors in the plasma membrane and activate membrane associated signaling cascades. Alternatively, these signaling cascades may be activated by acting on other unidenti®ed membrane binding sites (see Fig. 3 ). Estradiol may also act on conventional nuclear receptors and regulate transcription of growth factor receptors, cytoskeletal proteins and antiapoptotic molecules, all of them resulting in neuroprotection. modulation of cellular function have led to hypotheses that the trophic eects of estrogen and estrogen receptors involve complementary activation of transcription, via estrogen receptor binding to estrogen response elements, and estrogen receptor activation of signal transduction pathways, perhaps via ligand-induced release of constituents of the multimeric complex of the estrogen receptor complex (see Toran-Allerand et al., 1999 for a discussion), or via a membrane receptor (Fig. 4) .
A putative membrane receptor for estrogen has been postulated for many years, (Ramirez and Zheng, 1996; Becker, 1999) , supported primarily by electophysiological studies that demonstrated rapid eects of estrogen on the activity of neurons in a variety of brain regions (Foy et al., 1984; Smith et al., 1987 Smith et al., , 1988 Kelly et al., 1999 ; and see reviews in Moss et al., 1997; Bicknell 1998; and Becker, 1999) and binding studies showing that estrogen binds to membrane fractions (Zheng and Ramirez, 1997) . In addition, immunoreactivity for the classically de®ned nuclear estrogen receptors (discussed below) has been identi®ed in axon terminals (Blaustein et al., 1992; Wagner et al., 1998) . It is now thought that at least one class of these putative membrane estrogen receptors is synthesized from the same transcripts as the nuclear receptors and has a similar anity for ligand (Razandi et al., 1999) . These membrane estrogen receptors appear to function in estrogen signal transduction, in that estrogen rapidly activated G proteins, increased inositol phosphate synthesis and increased adenylate cyclase activity in either ER-a or ER-b transfected Chinese hamster ovary cells (CHO cells). However, when either ER-a or ER-b was overexpressed in CHO cells, over 95% of ER-a and -b receptor protein was found in nuclear cell fractions, whereas less than 3% was found in membrane fractions (Razandi et al., 1999) . Whether the putative membrane estrogen receptors in the brain are derived from alternate post-translational processing of the classical nuclear estrogen receptor genes is not yet known. However, it is clear that rapid eects of estrogen, altering phosphorylation events or calcium release, could importantly modify the transcriptional regulatory eects of estrogen receptors, and may account for some of the``non-receptor'' mediated eects described above (see Section 3.2.1).
3.2.2.2. Estrogen receptor distribution in the central nervous system. Steroid autoradiography, immunocytochemistry and in situ hybridization have been used to localize estrogen receptors in the nervous system. Each method provides a unique perspective on estrogen receptor biosynthesis and activity. Of primary importance is that the patterns of estrogen receptor expression found with each method match very closely, with some occasional exceptions (Toran-Allerand et al., 1992b) . Extensive steroid autoradiographic studies have pointed to the remarkable evolutionary conservation of the regional distribution of estrogen receptor expression in the nervous system (Morrell and Pfa, 1983) .
The distributions of ER-a and ER-b largely overlap (Li et al., 1997; Shughrue et al., 1997b Shughrue et al., , 1997d ; the reader is referred to these articles for detailed descriptions of the precise distribution of ER-a and -b expressing cells in the brain), and the two receptor subtypes are expressed in the same cells in some regions (Shughrue et al., 1998) . The regions with the highest densities of cells expressing estrogen receptors are found in the forebrain, in the preoptic area, hypothalamus and amygdala, particularly in subdivisions of these regions that are vital to reproductive function (Pfa and Keiner, 1973; Warembourg et al., 1989; DonCarlos et al., 1991) , and in the peripheral nervous system, in the dorsal root ganglion (Sohrabji et al., 1994a; Taleghany et al., 1999) . Estrogen receptor beta mRNA expression is higher than ER-a expression in the paraventricular nucleus and much higher in the medial tuberal nucleus, whereas ER-a mRNA expression is much greater than ER-b expression in the ventromedial and arcuate nuclei of the hypothalamus.
The proportion of total cells that are estrogen targets in a brain region, and the amount of binding per cell, as determined using steroid autoradiography, is highest in the medial amygdala, followed by the ventromedial nucleus, preoptic area and arcuate nucleus (Morrell et al., 1986) . Immunocytochemical studies of estrogen receptor alpha protein have found a roughly similar pattern (e.g., Wood and Newman, 1995) . The development of antibodies and mRNA detection methods for localization of estrogen receptors has provided enhanced sensitivity for identi®-cation of cells with lower levels of estrogen receptor expression per cell, as is characteristic for estrogen target areas that are not classically identi®ed with reproduction. Although the amount of estrogen receptor per cell and the total proportion of cells that are estrogen targets in areas such as the cerebral cortex, hippocampal formation, and midbrain raphe may be lower than found in the hypothalamus and amygdala, nevertheless the total number of such cells may in fact be much greater overall than found in the hypothalamus-preoptic continuum and amygdala. Therefore, the potential impact of estrogen, via estrogen receptor activation, in extra-hypothalamic, extra-amygdaloid regions should not be underestimated.
There is little doubt that the preponderance of highlevel estrogen receptor expression, that is amount of protein per cell, occurs in neurons under normal conditions. A steroid autoradiographic study, using a highly sensitive iodinated synthetic estrogen, showed that estrogen concentrating cells are immunopositive for neuro®lament protein, but not glial ®brillary acidic protein (Brown et al., 1993) . However, as discussed below, low levels of estrogen receptor immunoreactivity have been identi®ed in oligodendrocytes and astrocytes of the hypothalamus, using ultrastructural techniques (Langub and Watson, 1992) . Moreover, using confocal microscopy to detect cells double labeled for estrogen receptor and glial markers, estrogen receptors have been identi®ed in astrocytes (Azcoitia et al., 1999c) , microglia (Mor et al., 1999 ) and a variety of other glial cell types (Gudino-Cabrera and Nieto-Sampedro, 1999) . Given that glial cells outnumber neurons, it is possible that more glial cells express estrogen receptor than do neurons, albeit at much reduced levels. Quantitative studies to determine the proportion of speci®c glial cell types that express estrogen receptor alpha and beta, and the frequency of these cells in dierent brain regions, remain to be performed.
In many regions of the adult rat nervous system, levels of ER-a mRNA expression are higher in females than in males. Generally, estrogen down-regulates ERa mRNA, but even when estrogen levels are at their highest and ER levels at their lowest, adult females exhibit higher levels of ER-a mRNA (Simerly and Young, 1991; Shughrue et al., 1992) and ER protein (Zhou et al., 1995) than do males; males apparently have a lower capacity to synthesize ER. It is not known whether this sex dierence in synthetic capacity is limited to speci®c brain regions and normal versus injured brains. To date, there is little information about hormonal regulation and sexual dierentiation of ER-b expression.
With regard to neuroprotection and estrogen receptor regulation, aromatase levels and estrogen receptor levels (Dubal et al., 1999) are upregulated following injury to the central nervous system. We would have predicted that increases in local estrogen synthesis would be accompanied by decreased ER synthesis, the opposite of what actually occurs. The increase in ER-a expression is restricted to those areas that express high levels of ER during development. Together, these data support the argument that injury initiates a survival response that requires enhanced levels of both ligand and receptor. What neurotransmitters or other factors are released upon injury and participate in the upregulation or disinhibition of estrogen receptor synthesis is an open question. Noradrenaline is one neurotransmitter implicated in modulation of estrogen receptor levels and responses to estrogen under normal conditions (Clark et al., 1985; Tetel and Blaustein, 1991) .
The localization of estrogen receptors is not the only factor determining the role of estrogen within a given area. Estrogen receptor activation has regionally speci®c consequences. A key example of this is found in the anteroventral preoptic area (AvPv) and sexually dimorphic nucleus of the preoptic area (SDN-POA). Both areas express estrogen receptors during development (Kuhnemann et al., 1994; DonCarlos and Handa, 1994; DonCarlos et al., 1995) , and are functionally related, yet estrogen promotes survival of SDN-POA neurons (Dohler et al., 1984) and death of AvPv neurons (Arai et al., 1996; Davis et al., 1996) . In addition to demonstrating that estrogen can exert opposite eects in related estrogen receptor expressing regions, these ®ndings also serve to underscore the fact that estrogen may not be universally neuroprotective.
Estrogen receptor mediated neuroprotection.
Several lines of evidences suggest that neuroprotective eects of estradiol may be at least in part mediated by the activation of estrogen receptors. The neurotrophic action of estradiol in primary hippocampal cultures is reduced by substances, such as geldanamycin, that disrupt mature steroid receptor complexes (Gold et al., 1999) . Molybdate (20 mM), which prevents the disruption of mature steroid receptor complexes, also decreases the neurotrophic activity of estradiol (Gold et al., 1999) . This ®nding indicates that components of steroid receptor complexes may be involved in the neuroprotective eect of the hormone. A direct proof of the involvement of estrogen receptor on cell survival has been obtained in PC12 cells. Estrogen enhances the survival of PC12 cells transfected with the fulllength rat estrogen receptor alpha, but does not aect the survival of control cells transfected with vector DNA alone (Lustig, 1996; Gollapudi and Oblinger, 1999a; . There is also evidence that estrogen receptor is involved in the regulation of neuronal survival in primary cultures. Estrogen enhancement of neuronal survival in primary hypothalamic cultures in the serum-free medium and in cortical cultures exposed to glutamate is blocked by the estrogen receptor antagonists tamoxifen (Chowen et al., 1992; Singer et al., 1996b) and ICI 182, 780 (DuenÄ as et al., 1996; Singer et al., 1999) . In addition, antiestrogens abolish the neuroprotective action of 17b-estradiol in cultures of dorsal root ganglion neurons deprived of nerve growth factor (Patrone et al., 1999) . All of these ®ndings provide evidence that estrogen may promote neuronal survival in vitro by an eect mediated via estrogen receptors. The dependence of neuroprotective eects of estradiol on estrogen receptors has been demonstrated in vivo as well. The intracerebroventricular administration of the estrogen receptor antagonist ICI 182, 780 inhibits the neuroprotective eect of estradiol in hippocampal hilar neurons of ovariectomized rats exposed to systemic kainic acid . Furthermore, the selective estrogen receptor modulator raloxifene prevents MPTP-induced dopaminergic depletion in mice .
Potential molecular targets of estrogen receptormediated neuroprotection
3.2.3.1. Regulators of synaptic sprouting and axonal regeneration. It is well established that estradiol regulates synapse formation during development and induces synaptic plasticity in the adult brain (Matsumoto, 1991; Garcia-Segura et al., 1994; McEwen, 1996; Woolley, 1998) . These hormonal eects are involved in the sexual dierentiation of synaptic connectivity and in the physiological regulation of adult brain function. In addition, since the pioneering work of Matsumoto and Arai (1979) , it has been known that estrogen may promote synaptic sprouting in response to injury. These authors tested the eect of estrogen in the arcuate nucleus after deaerentation, a treatment that results in a loss of axo-dendritic synapses. Treatment with estradiol benzoate for three weeks, beginning on the day of surgery, eectively restored the axodendritic synaptic population of the deaerented arcuate nucleus in adult ovariectomized rats (Matsumoto and Arai, 1979, 1981) . Further studies have shown that the arcuate nucleus of aged female rats still retains plasticity to react to deaerentation under the in¯uence of estrogen (Matsumoto et al., 1985) . Other studies have shown that estrogen enhances synaptic sprouting in the hippocampus of ovariectomized female rats after entorhinal cortex lesions (Morse et al., 1986 (Morse et al., , 1992 and that estrogen accelerates regeneration rates of injured facial motoneurons (Tanzer and Jones, 1997) .
Many dierent molecules, including cytoskeletal components, adhesion molecules and soluble factors, participate in the process of axonal growth and axonal target recognition. These molecules include growth factors and neurotrophins (Fig. 4) . The possible role of growth factors and neurotrophins in the neuroprotective eects of estradiol is discussed in Section 3.2.3.3. Little is known about the role of adhesion and guidance molecules, such as semaphorins, on the neuroprotective eects of estradiol. In contrast, it is known that estradiol induces the expression of tau in axons and this may result in the stabilization of microtubules and the promotion of axonal growth (Ferreira and Caceres, 1991; Lorenzo et al., 1992; Diaz et al., 1992) . Another protein that may be involved in estrogeninduced axonal regeneration is GAP-43. GAP-43, also known as B-50, is a presynaptic protein implicated in the growth and regeneration of axons (Oestreicher et al., 1997) . The expression of GAP-43 is modulated by estrogen in the preoptic area of developing and adult rats (Shughrue and Dorsa, 1993) and in the mediobasal hypothalamus of adult rats (Lustig et al., 1991) . Levels of GAP-43 decline in aged rats. Interestingly, estrogen restores GAP-43 mRNA in 24 month old rats to levels comparable to that seen in young animals (Singer et al., 1996a) .
The eect of estrogen on synaptic sprouting may be mediated by the up-regulation of ApoE expression (Stone et al., 1998a; Teter et al., 1999) . ApoE is involved in lipid and cholesterol metabolism and it may be involved in the mobilization and reutilization of lipid in the repair, growth, and maintenance of myelin and axonal membranes, both during development and after injury. Furthermore, the epsilon 4 allele of ApoE has a direct impact on cholinergic function in Alzheimer's disease (Poirier, 1994 ; see also Section 2.1.2). The synthesis of ApoE is dramatically increased after injury of peripheral nerves (Ignatius et al., 1986; LeBlanc and Poduslo, 1990) and in the central nervous system (Poirier, 1994) . Although nerve regeneration may occur in ApoE de®cient mice (Popko et al., 1993; de Chaves et al., 1997) , these animals show an increased central neuronal damage after cerebral ischemia and other forms of cerebral injury (Chen et al., 1997a (Chen et al., , 1997b Sheng et al., 1999; Horsburgh et al., 1999) , suggesting that ApoE may be a factor involved in brain repair. Stone et al. (1998a) have shown that estrogen enhances synaptic sprouting in response to an entorhinal cortex lesion in wild-type and not in ApoEknock-out mice. Furthermore, synaptic sprouting is increased by estrogen in the same regions where sprouting is dependent on ApoE (Teter et al., 1999) .
3.2.3.2. Regulators of cell death. Estrogen's neuroprotective eects may involve, at least in part, a modulation of the expression of molecules involved in the control of cell death (Figs. 4 and 5) . The family of Bcl-2-related proteins is involved in the regulation of cell death of many cell types, including neurons. Some members of this family are negative regulators of cell death, such as Bcl-2 and Bcl-XL. Other members, such as Bax and Bad, are positive regulators of cell death. Estradiol has been shown to promote the expression of Bcl-2 in NT2 neurons (Singer et al., 1998) and in adult neurons in vivo and the expression of Bcl-XL in PC12 cells (Gollapudi and Oblinger, 1999a; Gollapudi and Oblinger, 1999b) and Fig. 5 . Described eects of estradiol on molecules that regulate programmed cell death. Estradiol downregulates the proapoptotic molecules Nip-2 and Par-4 and upregulates the antiapoptotic molecules Bcl-2 and Bcl-XL in neurons and neuronal cell lines. Acting on Bcl-2, estradiol may directly aect neuronal survival by blocking caspase activation and indirectly by the promotion of axonal regeneration. in cultured hippocampal neurons (Pike, 1999) . Identi®-cation of estrogen receptor target genes by mRNA dierential display PCR in human neuroblastoma SK-ER3 cells has revealed that the mRNA for the Bcl-2 interacting protein Nip2 is decreased by estrogen treatment . Nip-2 expression is also down-regulated by estradiol in monoblastoid cells (Vegeto et al., 1999) . Since Nip2 is a negative regulator of Bcl-2, estrogen may promote Bcl-2 expression by this mechanism (Fig. 5) . In addition, estradiol may directly aect transcription of bcl-2 gene, since several putative estrogen-responsive sites are present in the bcl-2 promoter (Teixeira et al., 1995) .
The hormonal regulation of the expression of the members of the Bcl-2 family is associated with the neuroprotective eects of estradiol. For instance, estradiol enhances the survival of PC12 cells transfected with the full-length rat estrogen receptor alpha and this eect is associated with an increased expression of Bcl-XL and a reduced expression of Bad (Gollapudi and Oblinger, 1999b ). An increased expression of Bcl-2 is associated with the hormonal protection of NT2 neurons from H 2 O 2 or glutamate induced cell death (Singer et al., 1998) . Estrogen signi®cantly increases the expression of the antiapoptotic protein Bcl-XL in cultured hippocampal neurons and this induction is associated with a reduction in apoptosis induced by beta-amyloid (Pike, 1999) . Furthermore, 17b-estradiol increases survival of cultured dorsal root ganglion neurons deprived of nerve growth factor and this eect is associated with an increased expression of Bcl-X without aecting the expression of Bax (Patrone et al., 1999) . Dubal et al. (1999) have found that estradiol prevents the down regulation of bcl-2 expression in the rat cerebral cortex induced by ischemia. Since this eect is accompanied by an increased ratio of estrogen receptor beta/estrogen receptor alpha expression, Dubal et al. (1999) propose that estradiol decreases the extent of cell death after ischemia by an estrogen receptor-beta mediated eect on Bcl-2. In addition to preventing neuronal death, Bcl-2 may also promote axonal growth and axonal regeneration (Chen et al., 1997a (Chen et al., , 1997b Holm and Isacson, 1999) . Therefore, by the induction of Bcl-2, estradiol may promote neuronal survival after injury both by Bcl-2-induced inhibition of cell death and by Bcl-2-induced facilitation of regeneration of neuronal connectivity (Fig. 5) . Furthermore, Bcl-2 attenuates the generation of reactive oxygen species (Bogdanov et al., 1999) and estradiol may therefore reduce oxidative stress in neural tissue by the induction of Bcl-2 expression.
Another protein that regulates cell death and is a target of estradiol is the prostate apoptosis response-4 (Par-4), the product of a gene up-regulated in prostate cancer cells undergoing apoptosis. Par-4 expression is induced in neurons after exposure to trophic factor deprivation and apoptotic insults (Guo et al., 1998; Chan et al., 1999; Duan et al., 1999a Duan et al., , 1999b and is up-regulated in vulnerable neurons in Alzheimer's disease brains (Guo et al., 1998) . Par-4 antisense treatment suppresses mitochondrial dysfunction and caspase activation in synaptosomes and prevents cell death of cultured hippocampal neurons following exposure to excitotoxic and apoptotic insults (Duan et al., 1999a) . Interestingly, both Par-4 induction and cell death induced by trophic factor deprivation in cultured hippocampal neurons are largely prevented by pretreatment of the cultures with 17b-estradiol . Since increases in Par-4 expression follow an increase of reactive oxygen species, and precede mitochondrial membrane depolarization, caspase activation, and nuclear chromatin condensation/ fragmentation, the down-regulation of Par-4 expression by estrogen may be one of the mechanisms involved in the antioxidant and neuroprotective eects of the hormone (Fig. 5) .
Growth factors
Neurotrophins. Since the pioneering work of ToranAllerand et al. (1992a ToranAllerand et al. ( , 1992b , it has been well established that estrogen and neurotrophins interact in many areas of the nervous system. Estrogen regulates the expression of neurotrophins and their receptors and neurotrophins regulate the expression of estrogen receptors in dierent neuronal populations. For instance, nerve growth factor signi®cantly increases nuclear estrogen binding in cortical explants (Miranda et al., 1996) . In turn, estrogen regulates the expression of p75 and of trkA in dorsal root ganglion neurons from adult rats (Sohrabji et al., 1994a) and in PC12 cells (Sohrabji et al., 1994b) . The hormone regulates the expression of mRNA for brain-derived neurotrophic factor and nerve growth factor in the hippocampus and frontal cortex (Simpkins et al., 1997a) , decreases the expression of NGF in the hippocampus and of trkA in the medial septum and nucleus basalis magnocellularis (Gibbs et al., 1994) and increases the expression of trkA in the basal forebrain of adult female rats (McMillan et al., 1996) . By decreasing the expression of brain-derived neurotrophic factor, estrogen induces dendritic spine growth in hippocampal neurons (Murphy et al., 1998) . This co-regulation of neurotrophins and estrogen receptors may be regulated by cell to cell interactions or may occur in the same neuron, since estrogen receptors and neurotrophin receptors are coexpressed in some cells.
In 1992, Toran-Allerand et al. reported that estrogen receptors colocalize with p75, the low-anity nerve growth factor receptors, in cholinergic neurons of the basal forebrain (Toran-Allerand et al., 1992b) . Further studies have shown a widespread colocalization of estrogen and neurotrophin receptors within estrogen and neurotrophin targets, including neurons of the cerebral cortex, sensory ganglia and PC12 cells (Sohrabji et al., 1994a (Sohrabji et al., , 1994b Miranda et al., 1994; Toran-Allerand, 1996; Toran-Allerand et al., 1999) . These ®ndings indicate that estrogen and growth factors may act in concert on the same neuron to regulate the expression of speci®c genes that may in¯uence neuronal survival (Toran-Allerand et al., 1992b; Toran-Allerand, 1996) . Furthermore, the colocalization of estrogen receptors and neurotrophin receptors in the same neurons leads to convergence or cross-coupling of their signaling pathways. In addition, estradiol may directly activate the signaling pathways of growth factors without the involvement of intracellular estrogen receptors. For instance, estradiol has been shown to elicit rapid and sustained tyrosine phosphorylation and activation of the mitogen-activated protein kinases ERK1 and ERK2 in cerebral cortical explants and neuroblastoma cells. ERK activation is not inhibited by the estrogen receptor antagonist ICI 182,780 and may depend on an increase in B-Raf kinase activity (Watters et al., 1997; Singh et al., 1999; Toran-Allerand et al., 1999) . In addition, estrogen induced neuroprotection in primary cortical cultures exposed to glutamate is associated with a rapid activation of tyrosine kinase and MAPK activity (Singer et al., 1999) .
It is still unknown whether estrogen and neurotrophins act in concert to promote neuronal survival after neural injury in vivo. However, an interaction of estrogen and NGF has been documented in terminally differentiated PC12 cells transfected with the estrogen receptor alpha. Estrogen and NGF act synergistically to protect these cells from apoptosis induced by serum deprivation (Gollapudi and Oblinger, 1999b) . This synergistic eect was not observed in control PC12 cells transfected with vector DNA (Gollapudi and Oblinger, 1999b) , suggesting that the synergistic action of estrogen and NGF on neuroprotection is dependent on estrogen receptor. Further studies are still needed to determine the extent of the interaction of estrogen and neurotrophins in dierent models of brain injury.
Insulin-like growth factor I. Insulin-like growth factor I (IGF-I) has prominent neurotrophic eects, stimulating dierentiation and survival of speci®c neuronal populations (Torres-Aleman et al., 1990 De Pablo and De la Rosa, 1995) . Trophic eects of IGF-I are mediated by IGF-I receptor, a member of the growth factor tyrosine kinase receptor family that signals through the phosphoinositol-3 kinase pathway and the mitogen-activated protein kinase (MAPK) cascade. IGF-I and estrogen have interactive eects on neurons. The ®rst evidence for this was provided by Toran-Allerand et al. (1988) , showing that in explant cultures of fetal rodent hypothalamus, estrogen and insulin have a synergistic action on neuritic growth, an eect probably mediated by IGF-I receptors. Subsequent studies showed that estrogen modulates IGF-I receptors and binding proteins in monolayer hypothalamic cultures (Pons and Torres-Aleman, 1993) . Both IGF-I and estrogen promote survival and dierentiation in primary hypothalamic cultures. Interestingly, in this system the eect of estrogen is dependent on IGF-I and the eect of IGF-I is blocked by the estrogen receptor antagonist ICI 182, 780 (DuenÄ as et al., 1996) . Furthermore, IGF-I receptor activation is necessary for estrogen induction of glial and synaptic plasticity in the hypothalamus in vivo (Fernandez-Galaz et al., 1997 .
The possible interaction of the neuroprotective eects of estradiol and IGF-I after injury have also been tested in vivo, by assessing neuronal survival in the hilus of the dentate gyrus after systemic administration of kainic acid to ovariectomized rats. Either IGF-I or estradiol is able to protect hippocampal neurons from kainic acid-induced degeneration (Azcoitia et al., 1998 . The administration in the lateral cerebral ventricle of a speci®c IGF-I receptor antagonist, the peptide JB1, resulted in the prevention of the neuroprotective eects of estrogen in this model, indicating that the hormonal eect is dependent on IGF-I receptors. Furthermore, the neuroprotective eect of IGF-I was blocked by ICI 182,780, indicating that activation of estrogen receptors is necessary for the eect of IGF-I on hippocampal neurons. These ®ndings suggest that the neuroprotective eect occurs only when both IGF-I receptor and estrogen receptor signaling pathways are activated. Since the production of estrogen and its precursor androgens, as well as the production of IGF-I, decline with aging in humans (Lamberts et al., 1997) , the interaction of estrogen and IGF-I signaling in neuroprotection may be relevant to the increased vulnerability to neurodegeneration in old age.
Several points of convergence of IGF-I and estradiol signaling may be involved in neuroprotection. For instance, both estradiol and IGF-I activate MAPK. MAPK interferes with c-Jun N-terminal protein kinase activation, protecting cells from apoptosis (Cheng and Feldman, 1998) . On the other hand, it has been shown that IGF-I and other growth factors may activate estrogen receptors in dierent cell types, including SK-ER3 neuroblastoma cells transfected with the estrogen receptor. This activation may occur even in the absence of estradiol and it is exerted via the ras-pathway in SK-ER3 neuroblastoma cells (Agrati et al., 1997) . Therefore IGF-I may in part regulate neuroprotection by direct activation of estrogen receptors. Other possible molecules that may be involved in the convergence of estrogen and IGF-I actions are those of the Bcl-2 family, since both estradiol and IGF-I induce the expression of the antiapoptotic regulator Bcl-2 in adult rat brain . Another possible common target for estrogen and IGF-I is NF-kB. This transcription factor may be involved in the protection of neurons from excitotoxic injury, oxidative stress and amyloid-beta induced neuronal death (Heck et al., 1999; Kaltschmidt et al., 1999; Yu et al., 1999) . NF-kB mediates IGF-I induced neuroprotection (Heck et al., 1999) , the p65 subunit of NF-kB heterodimer represses estrogen receptors via a physical interaction (McKay and Cidlowski, 1998) , estrogen activates kB-speci®c proteins in the uterus (Shyamala and Guiot, 1992) and estrogen receptor alpha may regulate the expression of genes under the control of NF-kB response elements (Cerillo et al., 1998) .
Glia versus neurons
Estrogen may directly or indirectly target cellular components of the nervous system other than neurons. Indeed, the protective eect of estradiol in transient forebrain ischemia may be related in part to an improvement of the vasodilating capacity (Hurn et al., 1995; Pelligrino et al., 1998) and to prevention of brain capillary endothelial cell loss which may in turn reduce focal ischemic brain damage (Shi et al., 1997) . In addition, chronic estrogen depletion by ovariectomy enhances leukocyte adhesion in the rat cerebral circulation while estrogen repletion is accompanied by a signi®cant reduction in leukocyte adhesion .
Glial cells are an essential component of normal neural function as well as of the response of neural tissue to injury. There is now substantial evidence that glial cells are targets for steroid hormones (GarciaSegura et al., 1996; Jordan, 1999; Langub and Watson, 1992; Nichols, 1999; Vardimon et al., 1999; Finley and Kritzer, 1999) and participate in steroid synthesis (Koenig et al., 1995; Zwain and Yen, 1999) and metabolism (Melcangi et al., 1999) . Glial cells mediate dierent actions of gonadal steroids in the regulation of the development and plasticity of speci®c neuronal populations and in the control of neuroendocrine events Jordan, 1999; Melcangi et al., 1999; Mong and McCarthy, 1999; Ojeda and Ma, 1999) . Furthermore, glial cells may be involved in the regenerative and neuroprotective eects of gonadal hormones Jones et al., 1999; Melcangi et al., 1999; Nichols, 1999) .
Estrogen receptors have been detected in dierent populations of glial cells (Azcoitia et al., 1999c; Gudino-Cabrera and Nieto-Sampedro, 1999; Mor et al., 1999) and estrogen regulates the morphology and gene expression of glia Stone et al., 1998b) . Furthermore, estrogen may regulate the proliferation of glia and the formation of reactive gliosis: the hormone inhibits microglia proliferation in vitro (Ganter et al., 1992) and down-regulates the proliferation of astrocytes after injury and the accumulation of reactive astrocytes in the lesioned brain area in both male and female rats (Garcia-Estrada et al., 1993 . These eects of estrogen on gliosis may be a contributing factor for neural regeneration. Estrogen may regulate the production of cytokines by the gliotic tissue that may be deleterious for neurons. For instance, estradiol decreases the activation of NF-kB in cultured rat astroglial cultures following exposure to amyloid beta(1±40) and lipopolysaccharides . Although NF-kB expression in neurons may promote neuroprotection (see``Neurotrophins'', p. 45), this transcription factor is also a potent immediateearly transcriptional regulator of numerous proin¯am-matory genes. Estrogen may therefore decrease the in¯amatory response after brain injury by decreasing the activation of NF-kB in astrocytes. In addition, by acting on glial cells, estrogen may regulate the release of factors, such as growth factors and neurotrophins, that promote neuronal survival and axonal regeneration. One of these factors is ApoE (see Sections 2.1.3 and 3.2.3.1). As mentioned before (Section 3.2.3.1), ApoE is involved in the eects of estrogen on axonal sprouting. Interestingly, estrogen increases the expression of ApoE in astrocytes and microglia in vitro and in vivo (Stone et al., 1997) , suggesting that these two glial cell types may be involved in the reparative eects of estrogen in the central nervous system. Since immunoreactivity for estrogen receptor beta has been detected in both microglia and astroglia (Azcoitia et al., 1999c; Mor et al., 1999) , it is possible that estrogen may directly act on these cells to regulate the production of ApoE.
Glial cells, in addition to mediating hormonal eects, may also produce neuroprotective steroids, including estradiol. Aromatase, the enzyme that produces estrogen from androgen precursors, is induced de novo in astrocytes by the systemic administration of kainic acid or by introducing a cannula in the brain parenchyma of rats and mice . This ®nding suggests that local production of estrogen is one of the mechanisms used by the central nervous system to cope with neurodegeneration and emphasizes the signi®cance of estradiol as a neuroprotectant (Fig. 6 ).
Prospectives for future studies
Estrogen and adult neurogenesis
The ability to induce proliferation and functional incorporation of new neurons in the adult brain would represent the ultimate form of neuroprotection. It has been understood for some time that new neurons are in fact born and functionally incorporated into the olfactory neuroepithelium. More recently, adult neurogenesis has been recognized in many species and more than one brain region (Alvarez-Buylla and Lois, 1995), including the higher vocal center of song birds where neurons are replaced seasonally (Barnea and Nottebohm, 1994; Alvarez-Buylla and Kirn, 1997) , and the dentate gyrus of the hippocampal formation of mammals, where it was ®rst observed by Altman and Das (1965) .
A potential role for estradiol in production of hippocampal granule cells has been investigated by Gould et al. (1999) . These investigators found that, following injection with bromodeoxyuridine (BrdU), a thymidine analog that labels dividing cells, females had signi®-cantly more newly generated cells in the dentate gyrus than did males. The delay between ®nal division and incorporation into the granule cell layer was approximately 3 weeks. By 3 weeks (and even earlier), there was no overall sex dierence in the total number of granule neurons, perhaps because more of the newly generated cells die in females. Neurogenesis is not only dierent in males and females, it also¯uctuates with the estrous cycle. The number of newly generated cells in the dentate gyrus was 50% higher in females injected with BrdU on proestrus (estradiol levels high) versus females injected on estrus or diestrus (estradiol levels low). Estrogen treatment reversed ovariectomy induced decreases in the rate of neurogenesis. Moreover, the number of dying cells is altered by circulating hormones, since 40% fewer pyknotic cells were observed in proestrus females vs those sacri®ced at other stages of the cycle. Similarly, some investigators have found that estrogen promotes survival of newly generated neurons in the bird song control regions (Hidalgo et al., 1995; Burek et al., 1995) . Estrogeninduced alterations in neurogenesis may be direct or may involve estrogen-dependent modi®cations of the hypothlamo-pituitary-adrenal axis, since adrenal steroids inhibit proliferation of cells destined for the granule cell layer (Gould et al., 1992) , but this remains to be established. Brief mention should be made respecting one potential technical caveat in evaluating those studies that use BrdU as a marker for newly generated cells, particularly with respect to eects of estrogen on the genesis and survival of neurons. Kolb et al. (1999) recently reported that BrdU is toxic to the embryonic brain. Also, earlier reports had shown that BrdU interferes with estrogen signaling (Kallos et al., 1978; Garcia et al., 1981) . Con®rmation of BrdU results with results based on other techniques to identify proliferative populations is therefore warranted.
The functional signi®cance of continual replenishment of dentate granule cell neurons, and why estrogen modi®es replacement of neurons in the dentate gyrus is unknown. One proposal is that the continuous replacement of neurons in the dentate gyrus provides a refreshable repository for temporary processing of new information that is later moved elsewhere for long term storage . Neuron addition in the hippocampal formation does appear to be accelerated under conditions that require or enhance learning Huang et al., 1998; Kempermann et al., 1997) , as observed in the avian vocal control pathways (Nordeen, 1990; AlvarezBuylla and Kirn, 1997) . Higher estradiol levels may signal a physical (e.g. pregnancy) or environmental (e.g. change of season) challenge that requires augmented memory acquisition. Since neurogenesis in the hippocampus declines with age (Cameron and McKay, 1999) , as do estrogen levels at menopause, these concurrent events may precipitate decreased cognitive functioning with age in some individuals.
Potential estrogen-dependent alterations of neurogenesis may also be of considerable clinical interest with the development of neural stem cell technology for replacing lost neurons. In hamsters, androgens enhance the functional incorporation into the olfactory bulb of progeny derived from the subventricular zone (Huang et al., 1999) , and in mice, the hormones of pregnancy enhance neurogenesis (Kaba et al., 1988) . Estrogen may help to coax the dierentiation of endogenous or exogenously applied neural stem cells into regionally appropriate and transmitter speci®c phenotypes. One potential mechanism through which estrogen may modulate neuropoiesis could involve interactions with growth factors, as discussed in Section 3.2.3.3. For example, estrogen upregulates expression of brain derived neurotrophic factor (BDNF) Fig. 6 . Possible sources of estradiol for injured neurons in the central nervous system. Estradiol may reach neurons directly from the circulation (1), after local conversion of peripheral testosterone by reactive astroglia (2), and after local conversion of locally-formed testosterone by reactive astroglia (3). Route 1 is of particular signi®-cance in females while route 2 will be of particular signi®cance in males. Route 3 may operate in both sexes. mRNA and protein in numerous brain regions (Gibbs, 1999) , including the cortex and hippocampal formation (Singh et al., 1995) . BDNF, in turn, promotes generation and survival of neurons derived from subventricular zone precursors (Goldman, 1998; Zigova et al., 1998) . Exogenous epidermal growth factor (EGF) promotes dierentiation of subventricular zone progeny into astrocytes rather than neurons, whereas basic ®broblast growth factor-2 (FGF-2) promotes an increase in the total number of newborn cells and development of a neuronal phenotype in progeny Palmer et al., 1999) in the rat, and like other neurotrophic factors (Toran-Allerand, 1996) , may be regulated by estrogen in the brain. Therefore, it is conceivable that estrogen will modulate neuropoiesis and the fate of progeny via interaction with growth factors. It is clearly of vital clinical importance to evaluate the potential therapeutic role of estrogen in stimulation of proliferation and survival of endogenous neural stem cells, on the one hand, and on the other hand, in orchestration of topographically accurate migration and targeted dierentiation of transplanted neural stem cells.
Estrogen receptor regulation following injury
In development, estrogen receptors are transiently expressed at high levels in some areas where they are not expressed in adulthood, such as the facial motor nucleus (Hayashi, 1994) or are expressed at much lower levels in the adult than the neonate, as in the hippocampal formation (O'Keefe and Handa, 1990; O'Keefe et al., 1995) . Neural repair has been proposed to involve, in part, reinitiation of developmental programs by injured neurons. Estrogen receptors may therefore play a role in survival or dierentiation of neurons in these regions. Estrogen receptor expression is induced following injury (Dubal et al., 1999) in regions of the cerebral cortex that produce higher levels of receptor developmentally (Shughrue et al., 1990; Yokosuka et al., 1995) , and may play a protective role in both instances. Estrogen accelerates recovery of function of facial motor neurons following axotomy (Tanzer and Jones, 1997) , although recapitulation of developmental estrogen receptor expression does not appear to be involved . Whether estrogen receptor induction following neurologic impairment occurs only in those areas that express the receptors during development or adulthood or is a more global injury response is unknown. If estrogen receptors are proven to be uniformly bene®cial to the injury response, then, as discussed above for the induction of neurogenesis, means by which estrogen receptor expression can be selectively augmented in targeted regions should be sought.
Estrogenic ligands, receptors, and other mechanisms of action
A major area of current eort in endocrinology is the search for ligands that selectively target estrogen receptors in speci®c tissues and provide bene®ts, such as prevention of osteoporosis or heart disease, without promoting the development of hormone dependent cancers. Similarly, estrogenic ligands that act in speci®c regions on speci®c subsets of neurons or glia would be ideal, not only to prevent the potentially harmful peripheral eects of estrogen, but also because the positive versus negative eects of estrogen within the nervous system are likely to be brain region dependent. For example, estrogen is toxic to neurons in the arcuate nucleus of the hypothalamus, speci®cally those that produce b-endorphin (Desjardins et al., 1995) , where it is thought to accelerate the onset of reproductive senescence. Additionally, in the sexually dimorphic nucleus of the preoptic area of aging male rats, the loss of neurons is more severe following estrogen treatment (Hsieh et al., 1996) . Developmentally, estrogen has opposite eects on survival even in neighboring and functionally related neuronal populations, where it spares some neurons (for example, in the sexually dimorphic nucleus of the preoptic area) while killing others (anteroventral periventricular nucleus of the preoptic area) (Arai et al., 1996) .
The above discussion highlights the need to learn more about the various mechanisms of action of estrogen in normal function as well as neuroprotection. If the mechanism of action of estrogen is due to a nonspeci®c enhancement of neural activity, then the eects of estrogen in neuroprotection should be similar to those of other general stimulants. More needs to be known about the anti-oxidant eects of estrogen, such as the required dose, time-course, and best route of administration for maximal bene®ts from estrogen treatment. The eects of estrogen on blood¯ow and cholesterol deposition similarly need further study. The elusive membrane receptors for estrogen should be explored further, to understand both their normal function and whether activation of these membrane receptors is neuroprotective. Why do exogenous, but not endogenous, steroids protect (as demonstrated by some castration experiments showing that castration does not alter responses to lesion (e.g. Kujawa and Jones, 1991; Kujawa et al., 1993) . Jones and colleagues (Jones et al., 2000) have argued that one mechanism for steroid induced neuroprotection involves the heat shock proteins, which form part of the steroid receptor heteromeric complex in the ligand-free state. They argue that when ligand causes the dissociation of heat shock proteins from the receptor complex, the pool of liberated heat shock protein can initiate signaling cascades that accelerate regenerative responses following injury; similar mechanisms have been invoked by Toran-Allerand et al. (1999) . Thus, exogenous steroid exposure may eliminate the need for de novo synthesis of heat shock protein in response to injury. Studies to overexpress heat shock proteins following injury may answer this question.
Much remains to be learned about the regulation of the nuclear estrogen receptors in the nervous system, such as how expression of these receptors is altered by cyclical and maturational shifts in hormones, pregnancy hormones, environmental cues, nutritional status, and behaviors as well as by neural disease or trauma. For those neuroprotectve eects that are dependent on estrogen receptors, how are these receptors regulated following damage? Is their regulation speci®c to the type of damage incurred? Is recent exposure to estrogen necessary to maintain estrogen senstivity, such that acute estrogen treatment will not sustain survival mechanisms in elderly women because their estrogen receptor concentrations are too low? Are sex dierences in mental and neurological disorders correlated in some way with disturbances of steroid receptor expressing areas speci®cally? What neurotransmitters regulate expression of estrogen receptors, and do declines in speci®c neurotransmitters, for example, serotonin, aect responses to estrogen? Which speci®c coactivators or adapter proteins are expressed in the nervous system and can their expression and regulation be manipulated to enhance the neuroprotective eects of estrogen? Finally, the extent to which sex dierences in developmental exposure to steroid hormones alters responses to the protective eects of estrogen in adulthood is unknown.
Optimal estrogen administration in neuroprotection
Clinically, what is the time course of estrogen exposure required to promote protection? If very high doses are necessary, are acute treatments sucient? What is the eective window of time available to treat patients with acute lesions, or does the hormone need to be present at the time of injury to protect the brain? Is exogenously delivered estrogen as eective as endogenously formed hormone, and is it preferable, in terms of protection of the brain and protection from side eects, to administer a large, acute bolus of testosterone, and let the brain do the work of selecting the site for local synthesis of estrogen? Clearly, there are many questions to be addressed in future investigations on the clinical ecacy of estrogen in treatment of neurological diseases and injury.
Concluding remarks
Neuroprotection by estrogen holds great promise for improving the clinical management of selected neurodegenerative diseases and neural trauma. Under normal conditions, estrogen has diverse pleiotropic eects on the nervous system, beyond those eects that constitute essential components of hypothalamo-pituitarygonadal regulation or the control of reproductive behaviors. Similarly, the neuroprotective eects of estrogen might be expected to be diverse and broad-ranging. The balance between protective and toxic levels of estrogen may be lesion, region, and age-dependent, and should be carefully investigated. The opposing developmental eects of estrogen, promoting survival in some cell populations and death in others, and the negative impact of high levels of estrogen on survival in aging neuronal populations, are powerful reminders that caution must be used in predicting and exploiting the potential therapeutically bene®cial eects of estrogen on the nervous system.
Note added in proof
Since this review was prepared, two reports have been published that call into question the therapeutic use of estrogen in symptomatic Alzheimer's disease (Henderson et al., 2000; Mulnard et al., 2000) . These reports detail the results of separate randomized, double-blind, placebo-controlled clinical studies designed to test the potential of estrogen as a therapeutic agent in mild to moderate Alzheimer's disease patients. Although the length of treatment with conjugated equine estrogens was dierent in the two studies (4 or 16 weeks in the Henderson et al., study, and 1 year in the Mulnard et al., study) the results were similar: estrogen treatment did not prevent cognitive decline in women with mild to moderate Alzheimer's disease. In fact, estrogen treatment for 1 year was associated with a worsening of symptoms in these patients. These ®ndings agree with experimental data indicating that estrogen is neuroprotective when administered before or at the same time as the neurodegenerative stimulus but is not neuroprotective when administered after the neurodegenerative stimulus. In conclusion, both clinical and experimental data suggest that estrogen may act as a preventive agent for neurodegeneration, while the hormone is probably unable to act as a restorative agent in already degenerated neural tissue.
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